Our company
Drug production is a high-profile and important business.

We develop and manufacture the latest generation of high-quality and efficient drugs based on our wealth of hands-on experience and knowledge.

In everything we do, we are committed to the principles and values that are essential to us: taking care of health and improving the quality of life of those who need medication. Our strategic goal is to continue expanding the range of products, introduce new technology, and control the quality of raw materials and finished products.

Our highly qualified team is the most valuable asset of our company. These hard-working professionals help us to ensure successful development of our company.

Alexander Malin
PhD in Chemistry
Chief Executive Officer

Nativa operates in the frame of the Federal Targeted Program Development of the Pharmaceutical Industry in the Russian Federation in the Period Until 2020 and Beyond. The company is an active participant in the government's import substitution program for public procurement of pharmaceutical products. Nativa has its own research and development facilities with the full scale cycle in place, from pharmaceutical fine chemicals to ready-to-use medications.

The company's production facilities are located in Krasnogorsky district of Moscow region. An agreement has also been reached to cooperate with manufacturing sites in Ufa and Kursk. Our pharmaceutical production complies with the European Union Good Manufacturing Practice (EU GMP).

The company's strategic focus is on the development and launch of pulmonary drugs on the Russian market.

The company's plans for the years to come involve an expanded range of the most popular drugs, including vital and essential medicines not manufactured domestically and not protected by foreign patents in the Russian Federation. The company works closely with pioneering developers of complex process solutions and implements partner programs to share unique international experience and transfer innovative pharmaceutical technology to Russia.

Nativa offers a wide range of high-technology medicinal products for effective, high-quality and affordable treatment. Our products are available in all regions of the Russian Federation.

Mission
  • Taking care of health and improving the quality of our patients lives.

  • Gaining the absolute quality of our products due to the high-quality team of specialists and innovatory pharmaceutical decisions.

Strategy
  • Development and production of effective, qualitative and safe drugs

  • Wide assortment

  • Flexible prices

Values
  • High ethical principles and social responsibility

  • Professionalism and competence

  • Team spirit

  • Innovation technologies

  • Leadership

Company history
  • 2010

  • 2012

  • 2013

  • 2014

  • 2015

  • 2016

  • 2017

  • 2018

  • 2010

    Nativa LLC is founded – to create and sell pulmonary medicines.

  • 2012

    Launch of Russia’s 1st Imatinib generic.

  • 2013

    Launch of Ipratropium Bromide+ Fenoterol – the 1st local generic.

  • 2014

    Ingal LLC is incorporated to develop and produce original medical devices for inhalation and hyaluronic acid injections. Nativa acquired the Pulmomed LLC product portfolio.

  • 2015

    Launch of Russia’s 1st Bortezomib generic and 1st Unit Dose Dry Powder Inhaler Salmeterol + Fluticasone

  • 2016

    Nativa started marketing Glatiramer Acetate, Triptorelin Long and Tiotropium Bromide – the 1st generic versions in Russia.

    Nativa acquired the F-Sintez product portfolio. Oncon LLC is founded to develop and commercialize anticancer BIO products.

  • 2017

    Market authorization of Sunitinib, Dasatinib, Nilotinib, Sorafenib — 1st generics in Russia.

  • 2018

    Launch Lenalidomide the 1st generic in Russia.

Quality Policy

2016 - 2019 years

Nativa develops, manufactures, and supplies to the Russian market high-end efficient and safe medicinal products issued from a transparent scientific process. We pursue the strategic goal of reducing the dependence of the Russian pharmaceutical market on imported drugs.

Our mission is to improve health and quality of life of those who need medication. By employing a highly qualified team of experts and by using innovative pharmaceutical solutions, we make sure our products meet the highest quality standards there are.

Our key asset is the company's employees: bright people committed to their work. Responsible professionals with years of practice, they work hard to achieve their goals, and to improve their knowledge and competences every day. Native ensures that their well-being is stable today, and will be even better tomorrow.

The cornerstone of our business strategy is constant improvement of our products’ competitiveness and quality. We also seek to cut costs all by seeking ever improving customer satisfaction, even better financial performance, even higher job satisfaction - and higher production standards.

Our quality objectives will be attained through:

  • 1. An improved quality management system at all production stages in line with GOST R ISO 9001-2011 Quality Management Systems. Requirements and GOST R 52249-2009 Good Manufacturing Practice for Medicinal Products.

  • 2. Decisions taken in line with the Quality Policy and quality goals.

  • 3. The internal environment provided and maintained to encourage employees to pursue corporate objectives.

  • 4. Necessary resources allocated for the objectives, including human and financial resources.

  • 5. Clear distribution of authorities and extended responsibility of the employees at all production stages.

Each employee of the enterprise is responsible for compliance with the corporate Quality Policy.

The management of NATIVA LLC undertakes the responsibility and responsibility for implementing the quality policy and continuous improvement of the effectiveness of the pharmaceutical quality system.

Nativa established the following objectives to achieve its quality goals:

  • 1. To develop and put in place an integrated management system for the pharmaceutical company based on a process approach; to standardize the existing processes (to develop and update corporate standards, guidelines, and instructions regarding the company's key activities).

  • 2. To improve employees' performance and effectiveness by way of human resources management, systematic training, and introduction of an incentive program for the company's employees.

  • 3. To gain a competitive advantage for our products through regular monitoring and realization of market opportunities, a wider product range, and participation in public procurement.

  • 4. To enhance quality and efficiency of our production technology through better quality (equipment modernization, selection of packaging materials supplier), process validation, and self-inspections.

  • 5. To deliver raw materials, supplies, semi-finished products, and components of the required quality for the production process at competitive purchase prices.

  • 6. To ensure quality control at all production stages (100% quality control for active pharmaceutical ingredients, semi-finished products, and finished products).

  • 7. To increase sales of our products both in Russia and the CIS.

img

Production of the company "Nativa" is organized in accordance with the European level of guidance on good manufacturing practice for pharmaceutical companies - EU GMP (Good Manufacturing Practice). Certification for compliance with the requirements of GOST R ISO 9001-2008 has been completed.